Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro

Konstantin A. Krychtiuk(Ludwig Boltzmann Institute for Cardiovascular Research), Johann Wojta(Medical University of Vienna), Walter S. Speidl(University of Applied Sciences St Pölten), Julia Pisoni(Ludwig Boltzmann Institute for Cardiovascular Research), Andreas Zuckermann(Medical University of Vienna), Renate Hofer-Warbinek(Medical University of Vienna), Stefan Kastl(Medical University of Vienna), Sabine Rauscher(Medical University of Vienna), Gerald Maurer(European Society of Radiology), Svitlana Demyanets(Medical University of Vienna), Elisabeth Buchberger(Medical University of Vienna), Kurt Huber(Sigmund Freud Privatuniversität Wien), Rainer de Martin(Deaconess Hospital), Marion Gröger(Medical University of Vienna), Christoph Kaun(University of Vienna), A.Z. Aliabadi(Medical University of Vienna), Lukas Watzke(Medical University of Vienna)
Thrombosis and Haemostasis
October 2, 2014
10.1160/th14-06-0549
Cited by 36

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755